Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNotes PayablesOther Accumulated ExpensesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Universe Pharmaceuticals (UPC) Payables (2020 - 2025)

Universe Pharmaceuticals' Payables history spans 6 years, with the latest figure at $7.4 billion for Q3 2025.

  • On a quarterly basis, Payables rose 19.37% to $7.4 billion in Q3 2025 year-over-year; TTM through Sep 2025 was $7.4 billion, a 19.37% increase, with the full-year FY2025 number at $7.4 billion, up 19.37% from a year prior.
  • Payables hit $7.4 billion in Q3 2025 for Universe Pharmaceuticals, up from $6.2 billion in the prior quarter.
  • Over the last five years, Payables for UPC hit a ceiling of $7.4 billion in Q3 2025 and a floor of $4.1 million in Q1 2023.
  • Historically, Payables has averaged $1.7 billion across 5 years, with a median of $8.3 million in 2021.
  • Biggest five-year swings in Payables: crashed 100.0% in 2021 and later surged 61577.77% in 2024.
  • Tracing UPC's Payables over 5 years: stood at $9.6 million in 2021, then decreased by 27.3% to $7.0 million in 2022, then skyrocketed by 43.59% to $10.1 million in 2023, then surged by 61577.77% to $6.2 billion in 2024, then grew by 19.37% to $7.4 billion in 2025.
  • Business Quant data shows Payables for UPC at $7.4 billion in Q3 2025, $6.2 billion in Q3 2024, and $4.4 million in Q1 2024.